

Resource Summary Report

Generated by [RRID](#) on Aug 22, 2026

BCR/ABL P190 transgenic construct

RRID:Addgene_38185

Type: Plasmid

Proper Citation

RRID:Addgene_38185

Plasmid Information

URL: <http://www.addgene.org/38185>

Proper Citation: RRID:Addgene_38185

Insert Name: BCR/ABL P190

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:2179728](#)

Vector Backbone Description: Backbone Size:3000; Vector Backbone:pSK; Vector Types:construct for making transgenic mice; Bacterial Resistance:Ampicillin

Comments: The DNA construct was made by Guido Jenster and Nora Heisterkamp in several cloning and subcloning steps. The transgenic construct contains human BCR exon 1, intron sequences of human BCR and ABL genes, human ABL exon 2 and ABL cDNA sequences. The transgene expression is controlled by a 200-bp Sst I- Bgl II fragment of the murine metallothionein-1 (Mt1) promoter lacking glucocorticoid-responsive elements (PMID 8541551). This BCR/ABL fusion gene produces a P190 protein and is a model for Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in humans, which is caused by a chromosomal translocation that fuses the ABL proto-oncogene with breakpoint cluster region (BCR) sequences. Leukemia development is relatively rapid on inbred C57Bl/6J and CBA backgrounds and is slower on mixed genetic backgrounds. Mice transgenic for this construct on an inbred C57Bl/6J background are also available from Jackson labs stock 017833. The insert can be separated from the vector by digestion with Sst II.

Plasmid Name: BCR/ABL P190 transgenic construct

Record Creation Time: 20220422T222201+0000

Record Last Update: 20260815T081420+0000

Ratings and Alerts

No rating or validation information has been found for BCR/ABL P190 transgenic construct.

No alerts have been found for BCR/ABL P190 transgenic construct.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Witkowski MT, et al. (2022) NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nature immunology, 23(10), 1424.

Witkowski MT, et al. (2020) Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. Cancer cell, 37(6), 867.

Ma C, et al. (2020) Leukemia-on-a-chip: Dissecting the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche. Science advances, 6(44).